Quantifying the societal benefits of adult immunization against respiratory diseases in France: a benefit cost analysis

View Full Paper

Ask AI

Bookmark

Share

Key Points

This analysis aims to quantify the societal benefits of adult vaccination against respiratory diseases in France.
Conducted a benefit-cost analysis to estimate benefit-cost ratios (BCRs) and net benefits (NBs).
Monetized health outcomes using established methods and included all direct vaccination-related expenditures.
Performed scenario and sensitivity analyses to assess alternative program specifications.
France's respiratory immunization programs show a BCR ranging from €2.0 to €8.7 per €1 spent, with NBs of €9.7 to €72.6 billion.
Introducing adult RSV vaccination could increase NBs by approximately 6%-7% over the current scenario.
Achieving higher vaccination coverage could potentially increase NBs by 138%-175%.

We only have this paper's title and publication details.

Quantifies societal gains from adult vaccination in France, implying significant economic returns.

No takes yet. Share an insight, caveat, or question.

Napier et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share